The SARS-CoV-2 infection may behave differently in pregnant and postpartum women in theshort and long term. Several risk factors or medication use can interfere on disease'evolution and vertical transmission. Thus, due the current pandemic and the scarcity ofscientific studies involving pregnant women with covid-19 or positive serology, combinedwith the need to elucidate the behavior of this viral infection in pregnant women in ourpopulation, this study aims to evaluate the clinical and laboratory evolution,transplacental passage, gestational and neonatal outcomes in pregnancies with positiveSARS-CoV-2.
Not Provided
Diagnostic Test: SARS-CoV-2 serology
Serology test of SARS-CoV-2 for pregnant women
Inclusion Criteria:
- Pregnant women with clinical symptoms or positive serology for SARS-CoV-2
hospitalized or in delivery time;
- Asymptomatic pregnant women for SARS-CoV-2 during pregnancy and hospitalized for
delivery at HU-USP.
- Pregnant women diagnosed with SARS-CoV-2 prior to delivery and who, after the
quarantine period, followed prenatal care and delivered at the HU-USP or HCFMUSP.
Exclusion Criteria:
- Non-confirmation of maternal SARS-CoV-2 infection in pregnant women hospitalized or
in delivery time.
- Withdrawal of pregnant woman to continue in the study.
Rossana P Fracisco
São Paulo, Brazil
Investigator: Rossana P Francisco, PhD
Contact: +551126616209
rossana.francisco@hc.fm.usp.br
Rossana P Francisco, PhD
+551126616209
rossana.francisco@hc.fm.usp.br
Ana Claudia S Farche, PhD
+551126619280
anafarche@usp.br
Rossana P Francisco, PhD, Principal Investigator
Faculdade de Medicina da Universidade de São Paulo - FMUSP